RxDoctor Payments Data

Stephanie Phan, MD

Ophthalmology · Bellevue, WANPI 1902987993

Payments from drug & device makers

$1,432in general payments, 2019–2025

Across 30 payments — averaging $47.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$471
  • Alcon$345
  • Tarsus Pharmaceuticals, Inc.$164
  • Aerie Pharmaceuticals, Inc.$125
  • Sun Pharmaceutical Industries Inc.$116
  • Novo Nordisk$113
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432 in reported general payments places this provider in the 60th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$320,152
Medicare patients
994
Services billed
2,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine53$70,513
LumiganBimatoprost36$28,288
VyzultaLatanoprostene Bunod33$20,059
Alphagan PBrimonidine Tartrate30$16,987
RocklatanNetarsudil Mesylat/Latanoprost20$15,823
Cyclosporine28$12,792
Latanoprost642$9,442
SimbrinzaBrinzolamide/Brimonidine Tart17$5,665
Travoprost35$4,811
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$4,405
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat224$4,356
Timolol Maleate211$1,978
Prednisolone Acetate34$1,688
Brimonidine Tartrate107$1,602
Ketorolac Tromethamine57$1,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$15$115,788119 claims
Bausch & Lomb Americas Inc.Vyzulta$471$20,05933 claims
Aerie Pharmaceuticals, Inc.Rocklatan$125$15,82320 claims
AlconSimbrinza$345$5,66517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →